Drug
Placebo matched to atacicept
Placebo matched to atacicept is a pharmaceutical drug with 5 clinical trials. Historical success rate of 60.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
60.0%
Based on 3 completed trials
Completion Rate
60%(3/5)
Active Trials
0(0%)
Results Posted
167%(5 trials)
Terminated
2(40%)
Phase Distribution
Ph phase_2
5
100%
Phase Distribution
0
Early Stage
5
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 2Efficacy & side effects
5(100.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
60.0%
3 of 5 finished
Non-Completion Rate
40.0%
2 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(3)
Terminated(2)
Detailed Status
Completed3
Terminated2
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
60.0%
Most Advanced
Phase 2
Trials by Phase
Phase 25 (100.0%)
Trials by Status
completed360%
terminated240%
Recent Activity
0 active trials
Showing 5 of 5
completedphase_2
Atacicept in Combination With Rituximab in Subjects With Rheumatoid Arthritis (August III)
NCT00664521
terminatedphase_2
A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS)
NCT00642902
completedphase_2
Atacicept in Anti-Tumor Necrosis Factor Alpha-naïve Subjects With Rheumatoid Arthritis (AUGUST II)
NCT00595413
completedphase_2
A Phase 2 Dose-finding Study of Atacicept in Subjects With Rheumatoid Arthritis (AUGUST I)
NCT00430495
terminatedphase_2
Atacicept in Subjects With Optic Neuritis
NCT00624468
Clinical Trials (5)
Showing 5 of 5 trials
NCT00664521Phase 2
Atacicept in Combination With Rituximab in Subjects With Rheumatoid Arthritis (August III)
NCT00642902Phase 2
A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS)
NCT00595413Phase 2
Atacicept in Anti-Tumor Necrosis Factor Alpha-naïve Subjects With Rheumatoid Arthritis (AUGUST II)
NCT00430495Phase 2
A Phase 2 Dose-finding Study of Atacicept in Subjects With Rheumatoid Arthritis (AUGUST I)
NCT00624468Phase 2
Atacicept in Subjects With Optic Neuritis
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5